Smith, Martha

Smith, Martha was paid $89K by Medicaid between Jan 2018 and Feb 2022, across 10 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 66% of everything it billed.

33Billing provider infoSMITH, MARTHA
KNOXVILLE, TN 37909

33aNPI1922035492assigned 06/28/2006

33bProvider typeAnesthesiology Physician

28Total paid$89K

24GClaims8,630

24DCodes billed10

24AFirst – last monthJan 2018 – Feb 2022

Compared with peers

Next to other Anesthesiology Physician providers in Tennessee

Rank by total paid#21 of 64

Median peer was paid$14K

This provider vs. median6.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,851	$22K
2019	3,182	$38K
2020	2,539	$28K
2021	969	$0.00
2022	89	$0.00

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	66%	4,315	3,723	$58K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	13%	240	221	$12K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	9.3%	242	223	$8K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	5.1%	327	298	$5K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	2.8%	639	609	$2K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	2.4%	181	175	$2K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.0%	44	38	$911.41
64493		<1%	20	13	$534.06
99072		0%	123	102	$0.00
99000		0%	2,499	2,216	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.